Compounded semaglutide claims: what's actually happening

What did @thedominiquetay actually say?

Dr. Taylor's core message: a federal judge sided with the FDA, semaglutide is coming off the drug shortage list, and compounders can no longer produce "exact match" copies. She told viewers not to panic but to book an in-person appointment, because telehealth companies won't be able to keep supplying it the same way they have been.

She added that some compounding pharmacies can still make versions that include added ingredients like B12, which technically qualify as "traditional compounding" rather than copies. She also flagged that many clinics will simply stop offering semaglutide altogether if they can't get it through Novo Nordisk or Eli Lilly directly. The pitch at the end, to come see a provider "like me" in a brick-and-mortar office, is worth noting as context for who's giving this advice.

Does the science back this up?

The regulatory facts here are broadly correct, though some details are compressed in ways that could confuse patients. The FDA's shortage determination and the legal outcome are real, and the implications for compounding are significant.

In March 2025, the FDA officially declared that the semaglutide shortage was resolved, which triggered restrictions under 503A and 503B compounding rules. Section 503A of the Federal Food, Drug, and Cosmetic Act prohibits compounders from making copies of commercially available drugs that are not on the shortage list. A federal judge in the Northern District of Texas denied the Alliance for Pharmacy Compounding's (APC, not LFA as stated) request for a preliminary injunction, meaning the FDA's enforcement could proceed. The key regulatory distinction Dr. Taylor draws between "exact match" compounds and formulations with added active ingredients is real, but the FDA has also signaled scrutiny of those combinations, so presenting them as a clean workaround is an oversimplification. Research on semaglutide's efficacy comes from branded formulations: the STEP trials (Wilding et al., 2021, New England Journal of Medicine) established the weight loss evidence base for Wegovy, not for compounded versions.

What did they get wrong (or right)?

She got the broad strokes right. The court case outcome, the shortage list removal, and the downstream effect on telehealth platforms are all accurate. The recommendation to establish care with a licensed provider and document your treatment history is genuinely good advice, not just self-promotion.

What she got wrong, or at least blurry: she calls the organization "LFA" when it was the APC, the Alliance for Pharmacy Compounding, that brought the lawsuit. That's a minor error but it matters for anyone trying to follow up. More importantly, her framing that compounded semaglutide with B12 or other additives is still clearly available as a "traditional compound" is more optimistic than the current regulatory picture warrants. The FDA has not given a green light to additive combinations as a permanent workaround, and enforcement guidance on 503A compounders specifically addresses that point. She also says telehealth companies "are not going to be able to provide" compounded semaglutide, which is directionally true but varies by state, compounder licensing, and whether the clinic works with a 503B outsourcing facility versus a 503A pharmacy.

What should you actually know?

If you've been taking compounded semaglutide through a telehealth platform, your access is genuinely at risk, but the timeline and your specific options depend on where you live and who prescribed it.

Here's what the regulatory situation actually looks like right now. The FDA set an enforcement deadline of April 22, 2025, for 503B outsourcing facilities to wind down bulk semaglutide compounding. 503A pharmacies, which fill individual prescriptions, had a slightly different timeline. The injunction denial means the FDA can now enforce, but enforcement is not instantaneous. Some platforms have already stopped, others are still operating. The clinical concern here is real: abrupt discontinuation of semaglutide can lead to weight regain. The SURMOUNT and STEP extension data both show meaningful rebound after stopping GLP-1 therapy (Wilding et al., 2022, Diabetes, Obesity and Metabolism). If you've had success on this medication, the move is to talk to a licensed prescriber now, not after your supply runs out, about whether you qualify for branded Wegovy or Ozempic and what your insurance situation looks like. Patient assistance programs from Novo Nordisk exist and are worth asking about directly.